First look: how a new blood disorder drug behaves in damaged livers
NCT ID NCT07152288
Summary
This early-stage study aims to understand how a single dose of the experimental drug HSK39297 is processed by the body in people with mild to moderate liver problems, compared to people with normal liver function. It will enroll 24 adults with Paroxysmal Nocturnal Hemoglobinuria (PNH), a rare blood disease, to measure drug levels and check for safety. The main goal is to gather data on how liver health affects the drug, which is crucial for future dosing guidance.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking University First Hospital
RECRUITINGBeijing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.